Drug intelligence / Profile preview

Bu Shen Huo Xue Fang

Development stage
Phase 1
Modality
Small Molecules
Administration
Oral
01

Overview

Bu Shen Huo Xue Fang (BSHXF) is a traditional Chinese medicine (TCM) herbal formula used primarily for its kidney-tonifying and blood-activating properties. It is composed of multiple herbs—typically including Radix rehmanniae, Radix bupleuri, Semen cuscutae, Cortex eucommiae, Fructus lycii (goji berry), Radix angelicae sinensis (dong quai), Cornu cervi pantotrichum (deer antler), Herba cistanches, Myrrh, Rhizoma dulcis and Safflower—though the exact composition may vary by source[3][4]. The main active compounds identified in the decoction include aucubin, tanshinol and tanshinone II A[1]. BSHXF has been studied for several indications: - Intervertebral disc degeneration (IDD): It promotes nucleus pulposus cell viability and extracellular matrix deposition while inhibiting cell senescence and inflammation. Its protective effects are thought to involve modulation of NF-κB and Wnt signaling pathways as well as reduction of oxidative stress through metabolic pathway regulation[1][5]. - Osteoarthritis: The formula acts via multicomponent/multitarget mechanisms involving tumor necrosis factor signaling pathways among others; it relieves joint swelling/pain and improves function[4]. - Diabetic nephropathy: BSHX decoction alleviates podocyte injury in high-glucose conditions both in vitro and potentially in vivo by tonifying deficiency (“kidney”) and invigorating blood circulation according to TCM theory[3]. - Spinal cord injury neuroprotection has also been reported in animal models[2]. The mechanism of action is complex due to its multi-herb nature but centers on anti-inflammatory effects (NF-κB inhibition), antioxidative stress modulation via metabolic pathways such as glutathione metabolism/citrate cycle/tryptophan metabolism etc., promotion of tissue repair/regeneration processes at cellular level.

Brand names
Bushen Huoxue Fang
Other names
Bushen Huoxue formulaBSHXFBu-Shen-Huo-Xue decoction
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)BCL-2 (BCL-2 family)IL8 (C-X-C Motif Chemokine Ligand 8)IL-6 (Interleukin 6)JUN (Transcription factor Jun)JNK (Mitogen-activated protein kinase kinase kinase family)MMP9 (Matrix metalloproteinase-9)TP53 (Cellular Tumor Antigen p53 R175H)VEGFA (Vascular endothelial growth factor A)NF-κB

Beyond the preview

Go deeper on Bu Shen Huo Xue Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bu Shen Huo Xue Fang.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call